BioNTech shares soar 8% as COVID-19 vaccines drive revenue surge

Referenced Symbols

Shares in BioNTech BNTX, +5.06% surged 8% in premarket trading on Monday, after the German biotechnology group reported first-quarter earnings. Jointly with Pfizer PFE, +1.46% 0Q1N, +5.24%, BioNTech co-developed the first COVID-19 vaccine to receive the green light from regulators following large-scale clinical trials. The group reported revenue of €2.05 billion ($2.49 billion) in the first three months of the year, outpacing expectations for €1.7 billion, according to FactSet consensus. Revenue in the same period in 2020 was €27.7 million. Net profit surged €1.13 billion in the first quarter of 2021, up from €53.4 million in 2020. BioNTech said that it had supplied more than 450 million doses of its COVID-19 vaccine to 91 countries or territories as of May 6, with signed agreements for more than 1.8 billion doses in 2021. The estimated revenue from COVID-19 vaccine deliveries, based on the currently signed contracts, is €12.4 billion. The group said there was no evidence that its COVID-19 vaccine needed to be adapted to deal with variants of the virus that have been identified.

Read Next

Read Next

Trade Desk stock tumbles even after 10-for-1 stock split, profit and revenue that beat expectations

Shares of Trade Desk Inc. undefined tumbled 11.1 % toward a 6-month low in premarket trading Monday, even after the provider of advertising buying services reported better-than-expected first-quarter profit and revenue and announced a 10-for-1 stock split. The company said the stock split will be enacted in the form of a stock dividend, which will be distributed on June 16 to shareholders of record on June 9; the stock will start trading on a split-adjusted basis on June 17. Net income fell to $22.6 million, or 45 cents a share, from $24.1 million, or 50 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share rose to $1.41 from 90 cents and beat the FactSet consensus of 80 cents. Revenue grew 36.8% to $219.8 million, above the FactSet consensus of $216.9 million. Total operating expenses increased 41.5% to $212.0 million, with sales and marketing expenses climbing 62.6% and technology and development spending rising 46.5%. The company expects second-quarter revenue of between $259 million and $262 million, above the current FactSet consensus of $253 million. Trade Desk's stock has slumped 17.4% year to date through Friday, while the S&P 500 undefined has gained 12.7%.

More On MarketWatch

About the Author